Chief Legal Officer — Kashif Rashid: The company appointed an external candidate to fill the Chief Legal Officer role, which is a standard executive hiring event rather than a departure.

Results of Operations and Financial Condition On August 5, 2026, Sight Sciences, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended June 30, 2026 and raising its revenue guidance and reducing its adjusted operating expense guidance for the year ending December 31, 2026. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K (this “Current Report”).*

Results of Operations and Financial Condition On May 6, 2026, Sight Sciences, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2026. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K (this “Current Report").*

Regulation FD Disclosure. On April 22, 2026, Sight Sciences, Inc. (the “Company”) received notification that the U.S. District Court for the District of Delaware (the “Court”) entered its final judgment (the “Final Judgment”) regarding the patent infringement case (the “Litigation”) filed by the Company in September 2021 against Alcon Inc., Alcon Vision, LLC, Alcon Research, LLC, and Ivantis, Inc. (collectively, “Alcon”). The Company had asserted that Alcon’s sale of the Hydrus® Microstent (“…

Regulation FD Disclosure. On March 30, 2026, Sight Sciences, Inc. (the “Company”) issued a press release announcing that the U.S. District Court for the District of Delaware (the “Court”) issued an order preserving the jury’s verdict of willful infringement in the patent infringement case (the “Litigation”) filed by the Company in September 2021 against Alcon Inc., Alcon Vision, LLC, Alcon Research, LLC, and Ivantis, Inc. (collectively, “Alcon”). The Company had asserted that Alcon’s sale of…

Results of Operations and Financial Condition On March 4, 2026, Sight Sciences, Inc. (the “Company”) issued a press release announcing its financial results for the year and quarter ended December 31, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K (this “Current Report").*

Entry into a Material Definitive Agreement On January 29, 2026, Sight Sciences, Inc. (the “Company”) entered into that certain Second Amendment to Multi-Tenant Space Lease (the “Second Amendment”) with Deerfield Campbell, LLC (the “Lessor”), for the Company’s headquarters located at 4040 Campbell Avenue (Suites 100 and 120), Menlo Park, California 94025. The Second Amendment amends that certain Multi-Tenant Space Lease, dated February 5, 2021, and that certain Commencement Date/Acceptance Agr…

by reference. The information provided in this Item 2.02, including Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such f…

Results of Operations and Financial Condition On November 6, 2025, Sight Sciences, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended September 30, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K (this “Current Report).*

Chief Operating Officer — Alison Bauerlein: Alison Bauerlein was promoted to Chief Operating Officer and will no longer serve as Chief Financial Officer.

Other Events. Two Medicare Administrative Contractors (“MACs”), Novitas and FCSO, each established jurisdiction-wide pricing for CPT code 0563T (evacuation of meibomian glands, using heat delivered through wearable, open-eye eyelid treatment devices and manual expression, bilateral), which describes the procedure performed with the Company’s TearCare® System and related accessories (TearCare). The Medicare fee schedule amount of $1,141.59 is effective for dates of service on and after January…

Entry into a Material Definitive Agreement. Third Amendment to Loan and Security Agreement On September 30, 2025 (the “Amendment Date”), Sight Sciences, Inc. (the “Company”) entered into a third amendment (the “Amendment”) to its Loan and Security Agreement (as amended, the “Hercules Loan Agreement”) with Hercules Capital, Inc. (“Hercules”) and certain of its affiliates (collectively with Hercules, the “Lenders”) entered into in January 2024. The Hercules Loan Agreement provides for a senior…

Regulation FD Disclosure The Company reaffirms its prior revenue guidance for the year ending December 31, 2025 of $72.0 million to $76.0 million and reaffirms its expectation for third quarter 2025 surgical glaucoma revenue to be down by mid-single digits compared to the same period in the prior year. In addition, the Company estimates the workforce reductions associated with the Plan alone will yield savings of approximately $11.9 million on an annualized basis. The Company is updating its…

Chief Commercial Officer — Matthew Link: Matthew Link is leaving the company to pursue other opportunities.

Costs Associated with Exit or Disposal Activities On August 27, 2025, Sight Sciences, Inc. (the “Company”) informed its employees that it is implementing a targeted plan, commencing immediately, intended to reduce operating expenses, improve cost efficiencies, and better align its operating structure for long-term, profitable growth (the “Plan”). The Plan is designed to optimize the Company’s operating structure, help support the Company’s cash position, drive enhanced focus on the Company’s…

Results of Operations and Financial Condition On August 7, 2025, Sight Sciences, Inc. (the "Company") issued a press release announcing its financial results for the quarter ended June 30, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.*

Director — Gerhard F. Burbach: Mr. Burbach was appointed to the Board and will serve on the Audit Committee.

Results of Operations and Financial Condition On May 8, 2025, Sight Sciences, Inc. (the "Company") issued a press release announcing its financial results for the quarter ended March 31, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.*

Director — Gerhard F. Burbach: Mr. Burbach was appointed to the Board of Directors.

Results of Operations and Financial Condition On March 5, 2025, Sight Sciences, Inc. (the "Company") issued a press release announcing its financial results for the year and quarter ended December 31, 2024. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.*

The filing details the annual base salaries and target cash incentive bonus opportunities for certain executive officers, which is a routine compensation update.

of this Current Report, including Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing. SIGNATURES Pursuant to the…

Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant On December 10, 2024 (the “Closing Date”), Sight Sciences, Inc. (the “Company”) consummated the drawdown of the $5.0 million Tranche 1(b) Term Loan Advance (the “Tranche Loan”) contemplated by that certain Loan and Security Agreement (the “Loan Agreement”) by and among the Company, Hercules Capital, Inc. (“Hercules”) and certain affiliates of Hercules (collectively with Hercules,…

Unregistered Sales of Equity Securities On the Closing Date, as contemplated by the Loan Agreement, the Company issued warrants to the Lenders to purchase that aggregate number of shares of the Company’s common stock, par value $0.001 per share (“common stock”), equal to two percent (2.0%) of the principal amount of the Tranche Loan, or $0.1 million, divided by the volume-weighted average price of the common stock for the five-day period preceding the Closing Date. Each warrant is exercisable…

Results of Operations and Financial Condition On November 7, 2024, Sight Sciences, Inc. (the "Company") issued a press release announcing its financial results for the quarter ended September 30, 2024 and updating its adjusted operating expenses guidance for the full year 2024. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K (this "Current Report").*